Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713128 · ClinicalTrials.gov registry record
Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy
A clinical trial, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- Completed
- Registry status
- 50
- Enrollment target
NCT00713128 is a clinical trial that has completed, run by Steward St. Elizabeth's Medical Center of Boston. The registered enrollment target is 50 participants.
The verdict
NCT00713128 has completed, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This is a study to determine how much nausea and or vomiting is caused by irinotecan-based chemotherapy in patients with colorectal cancer. Patients with colorectal cancer scheduled to receive their first cycle of an irinotecan-based chemotherapy regimen are eligible. Any chemotherapy agents administered in combination with irinotecan must have low-minimal potential to cause nausea and or vomiting. Examples of acceptable regimens would be irinotecan in combination with infusional fluorouracil and leucovorin (FOLFRI) with or without bevacizumab and irinotecan in combination with cetuximab. Patients who have received prior non-irinotecan-based chemotherapy are eligible providing they experienced no vomiting and no greater than mild nausea with their prior chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713128
The ClinicalTrials.gov registry entry for NCT00713128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steward St. Elizabeth's Medical Center of Boston, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00713128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00713128 about?
NCT00713128 is a clinical study titled "Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy". This is a study to determine how much nausea and or vomiting is caused by irinotecan-based chemotherapy in patients with colorectal cancer. Patients with colorectal cancer scheduled to receive their first cycle of an irinotecan-based chemotherapy regimen are eligible. Any chemotherapy agents adminis...
What is the current status of trial NCT00713128?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2008-04. Estimated completion is 2009-12.
Who is sponsoring clinical trial NCT00713128?
This trial is sponsored by Steward St. Elizabeth's Medical Center of Boston, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.